Printer Friendly

RIBOZYME PHARMACEUTICALS HIRES DIRECTOR OF BUSINESS DEVELOPMENT

 BOULDER, Colo., Nov. 29 /PRNewswire/ -- Ribozyme Pharmaceuticals Inc. (RPI), a biotechnology company commercializing its patented, Nobel Prize-winning ribozyme technology, today announced that Gretchen von Gustlin, JD, has joined RPI as director of business development. She will begin her new activities at the beginning of 1994. The appointment of von Gustlin, who had been House Counsel at Sugen Inc., completes the senior management team at RPI in its current stage of development.
 "With her experience both in business development and law, Ms. von Gustlin is very well suited to take on a leadership role in RPI's business development activities," said Ralph E. Christoffersen, chief executive officer and president of RPI. "Her background includes experience with strategic alliances, initial public offerings, joint ventures, venture capital and other financing transactions, as well as licensing activities. Having a person with these excellent qualifications will enable RPI to accelerate activities in the business development area relating to developing ribozymes for commercial use."
 Von Gustlin's initial responsibilities will include existing collaborations with Parke Davis and DowElanco, as well as licensing arrangements with The University of Colorado and others. In addition, she will take a leadership role in the analysis of portfolio opportunities, financing options and various potential collaborative and licensing opportunities.
 Ribozymes are RNA molecules which are able to modify a cell's gene expression by enzymatically cleaving RNA at specific points. The ribozyme technology, for which RPI holds several broad patents, has equally broad commercial application potential in the human therapeutic, diagnostic, agricultural and veterinary fields. Products currently in development by RPI include ribozymes targeted against human immunodeficiency virus (HIV), osteoarthritis and several other disease targets.
 RPI was formed in 1992 with technology licensed from U.S. Biochemical Corp. and with an initial $6.0 million round of financing from venture capital sources. A second round of $12.0 million in venture capital financing was completed in December 1992, and corporate partner collaborations with Parke Davis and DowElanco were announced in April and September 1993, respectively.
 -0- 11/29/93
 /CONTACT: Ralph Christoffersen of RPI, 303-449-6500/


CO: Ribozyme Pharmaceutical Inc. ST: Colorado IN: MTC SU: PER

BB -- DV002 -- 8329 11/29/93 13:25 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 29, 1993
Words:359
Previous Article:LOWE'S ANNOUNCES NOVEMBER SALES
Next Article:ARCO GIFTS HELP PORT ANGELES AUTHORITIES PURCHASE EMERGENCY RESPONSE EQUIPMENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters